Patents Assigned to XIAMEN BIOFAST BIOTECHNOLOGY CO., LTD.
  • Patent number: 11459614
    Abstract: Disclosed herein is a method of performing polymerase chain reaction (PCR) to determine a repeating number of CGG sequence in fragile X mental retardation 1 (FMR1) gene. Also disclosed herein are a kit, and uses thereof in making a diagnosis of Fragile X syndrome (FXS) in a human subject based on the repeating number of the CGG sequence in a DNA sample isolated from the human subject. According to embodiments of the present disclosure, the kit comprises four primers, in which the first primer comprises a first polynucleotide sequence of SEQ ID NO: 1; the second primer comprises a second polynucleotide sequence of SEQ ID NO: 2; the third primer comprises a third polynucleotide sequence of SEQ ID NO: 3, and a non-human sequence disposed at and connected to the 5?-end of the third polynucleotide sequence; and the fourth primer comprises the non-human sequence.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: October 4, 2022
    Assignee: XIAMEN BIOFAST BIOTECHNOLOGY CO., LTD.
    Inventors: Yi-Yi Kuo, Yu-Chiao Hsiao, I-Fan Chiu, Lai-Ha Chung, Shu-Ju Lee